Europe Lymphedema Treatment Market Analysis, Size, and Share by 2028

The lymphedema treatment market in Europe is expected to grow from US$ 2,801.39 million in 2021 to US$ 3,953.12 million by 2028; it is estimated to grow at a CAGR of 5.0% from 2021 to 2028.

One report states that treatment plans are designed for determining the stages and causes of the condition. For example, surgeons performed several reconstructive surgical interventions, including vascularized lymph node transfer, lymphovenous bypass, and a type of liposuction for reducing swelling. Additionally, the non-surgical techniques include complete decongestive therapy (CDT). Several hospitals are equipped with beds that perform CDP on patients due to satisfactory medical coverage. New tests, coupled with technological advancements, play a critical role in controlling the prevalence of lymphedema cases among patients. On the other hand, the lymphedema management program provides services related to physical and occupational therapists that have been extensively trained in skilled treatment techniques for lymphedema management. One major company has developed a rehabilitation program based on therapists' training and working knowledge of current medical management of primary and secondary lymphedema with rehabilitative needs. Also, services by physical and occupational therapists are brought together for developing a personalized treatment plan for restoring the patient to the highest level of functioning. A major aim of such an innovative rehabilitation program is to educate and instruct patients about self-assist techniques for managing primary and secondary lymphedema independently. So, increasing healthcare services and lymphedema management programs is expected to fuel the market growth.Countries in the European regions were profoundly affected due to the COVID-19 pandemic. For instance, countries such as Italy, Spain, and France have reported the highest number of positive cases and have registered the maximum number of deaths. For instance, according to the Worldsometer, as of January 2022, 101,188,010 total cases, and 1,565,203 deaths have been registered due to COVID–19 in Europe. Countries across Europe are witnessing a resurgence in COVID-19 cases after successfully mitigating outbreaks early in the year. Many countries are declaring more cases each day now than during the first wave earlier last year. Lockdowns are being reintroduced in the UK, Spain, Italy, and Ireland, as per the European Centre for Disease Prevention and Control (ECDC). Due to the second wave of COVID-19 cases, many countries' government is working towards boosting up their treatments and regenerative medicines technologies for development of various diseases including COVID-19. Additionally, in the UK, the practice of cancer and neurological diseases has changed. Increasing COVID-19 has affected the diagnosis and treatment of diseases, due to the diversification of the medical workforce and decision to focus on treating the critically ill. Due to the current pandemic, many research organizations, are focusing more on COVID 19 studies and are working hard to better understand the virus. The lymphedema treatment market witnessed a shortfall at the beginning of the COVID-19 crisis due to disruption in the supply chain and slumped demand of medical devices (used for the treatment of lymphedema) due to the lockdown announced by most European countries that caused disruptions in manufacturing and operations in the sector. Additionally, appointments and operations have been delayed in many clinics around the world due to increasing cases, as approximately 40% of the diagnosed COVID-19 cases required hospitalisation; and some critical cases were admitted to intensive care units (ICU). According to an article in Vascular News, in the first week of the pandemic outbreak, there was an 80 percent reduction in beds and an 84 percent reduction in operating rooms for elective procedures, with 43 percent of hospitals in Italy not doing any elective surgery. With the number of rising cases, there was a significant decrease in procedures due to a lack of healthcare resources. It also impacted the new product launches, impacting sales and growth of the market in the region. However, with the implementation of proper guidelines and protocols by the European Commission to reduce SARS-CoV-2 exposure and ease in restrictions on movement, the market is expected to grow in the forecast period.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the lymphedema treatment market. The Europe lymphedema treatment market is expected to grow at a good CAGR during the forecast period.

Europe Lymphedema Treatment Market Revenue and Forecast to 2028 (US$ Million)

                                     

 

Europe Lymphedema Treatment Market Segmentation

Europe Lymphedema Treatment Market – By Condition Type

• Primary Lymphedema
• Secondary Lymphedema

Europe Lymphedema Treatment Market – By Treatment Type

• Laser Therapy
• Compression Devices
• Drug Therapy
• Physiological Procedures
  • Lymphovenous Anastomosis (LVA)
  • Vascularised Lymph Node Transfer (VLNT)
• Debulking Procedures
  • Surgical Debulking
  • Liposuction
  • Others
• Others

Europe Lymphedema Treatment Market – By End-User

• Hospitals
• Clinics
• Clinical Research Organizations
• Others

Europe Lymphedema Treatment Market- By Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest of Europe

Europe Lymphedema Treatment Market-Companies Mentioned

• 3M Company
• BSN medical GmbH
• Huntleigh Healthcare Limited
• Lohmann & Rauscher GmbH & Co. KG
• Mego Afek ltd
• Sigvaris Group
• Smith & Nephew

Europe Lymphedema Treatment Report Scope